Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2007

View Archived Issues

Variation Biotechnologies raises Series A financing

Preclinical characterization of sergliflozin, a novel selective SGLT2 inhibitor

Poniard and Scripps Research Institute to discover FAK inhibitors

Icagen updates sodium channel programs

Scynexis earns preclinical milestone payment from Merck collaboration

AstraZeneca and Bristol-Myers Squibb collaborate on type 2 diabetes compounds

MultiCell's anticancer combination therapy prevents disease recurrence

Biomedical Research Models licenses Neuralstem compounds in diabetes

Valeant and Metabasis close pradefovir licensing deal with Schering-Plough

CytRx establishes new RNAi subsidiary, RXi Pharmaceuticals

Droxidopa reduces fall in orthostatic systolic blood pressure

Astellas terminates agreement on carperitide for acute heart failure

Progress in phase I study of anticancer compound ECO-4601

Valeant licenses Canadian rights to Xyrem in cataplexy

BioInvent and Genentech collaborate on cardiovascular candidate BI-204

Stimuvax begins phase III study

FDA outlines issues regarding planned phase I study of ReN-001 stem cell therapy

Metastatic pancreatic cancer patients show clinical responses to talabostat therapy

Sativex shows utility in peripheral neuropathic pain

Promising preclinical results with raloxifene-derived selective estrogen receptor modulator

Mycamine launched in 100 mg vial format

Somatuline Autogel NDA accepted for filing

Novel TAFIa inhibitor profiled at Berlex

Recent sanofi-aventis patents report novel therapeutic agents for arrhythmia

Novel treatment options for HIV infection reported in recent patent literature

Recent Gruenenthal patent discloses new analgesic agents

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...